<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033500</url>
  </required_header>
  <id_info>
    <org_study_id>H-2010-0042</org_study_id>
    <nct_id>NCT01033500</nct_id>
  </id_info>
  <brief_title>Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients</brief_title>
  <official_title>Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that a calcineurin inhibitor-free, steroid-free, co-stimulatory&#xD;
      blockade-based immunosuppressive regimen, in combination with a GLP-1 agonist, will reduce&#xD;
      the islet mass required to achieve and sustain insulin independence following simultaneous&#xD;
      islet-kidney transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label, non-randomized, prospective, pilot study of 8 Type 1&#xD;
      diabetic/uremic patients, ages 18-60 undergoing simultaneous islet-kidney transplantation.&#xD;
      Study to include both male and/or female subjects.&#xD;
&#xD;
      We hypothesize that a calcineurin inhibitor-free, steroid-free, co-stimulatory blockade-based&#xD;
      immunosuppressive regimen, in combination with a GLP-1 agonist, will reduce the islet mass&#xD;
      required to achieve and sustain insulin independence following simultaneous islet-kidney&#xD;
      transplantation.&#xD;
&#xD;
      Furthermore, we anticipate an improvement in creatinine clearance and a reduction in&#xD;
      Interstitial Fibrosis/Tubular Atrophy in the transplanted renal allograft, and a reduction of&#xD;
      &quot;de novo&quot; human anti-HLA antibody and auto-antibody formation against the respective donors.&#xD;
&#xD;
      Without calcineurin inhibitors or steroids, we hypothesize that belatacept, in conjunction&#xD;
      with sirolimus and mycophenolic acid will provide balanced immunosuppression for combined&#xD;
      islet-kidney transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient funding&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Islets of Langerhans Transplantation</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>SIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.</description>
    <arm_group_label>SIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will include those with Type 1 Diabetes Mellitus, undergoing kidney&#xD;
             transplantation, and:&#xD;
&#xD;
               -  are closely followed by a primary care provider and/or endocrinologist for &gt;6&#xD;
                  months prior to enrollment in the trial&#xD;
&#xD;
               -  do not have psychogenic factors which preclude therapeutic compliance&#xD;
&#xD;
               -  have a fasting C-peptide of &lt;0.2 ng/mL• have diabetes for &gt;5 years • are between&#xD;
                  18 and 65 years of age&#xD;
&#xD;
               -  have a creatinine clearance of less than 20 mL/min&#xD;
&#xD;
               -  have a body mass index of less than or equal to 28&#xD;
&#xD;
               -  In the case of women of childbearing potential (WOCBP), must have a negative&#xD;
                  pregnancy test and avoid pregnancy throughout the study and 8 weeks after final&#xD;
                  dose of study drug.&#xD;
&#xD;
               -  WOCBP must use two adequate methods of contraception.&#xD;
&#xD;
               -  A male subject of fathering potential must use an adequate method of&#xD;
                  contraception to avoid conception throughout the study and for up to 8 weeks&#xD;
                  after the last dose of study drug to minimize the risk of pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated proliferative diabetic retinopathy&#xD;
&#xD;
               -  HgbA1C &gt;12&#xD;
&#xD;
               -  creatinine clearance &gt; 20 ml/minute&#xD;
&#xD;
               -  presence of panel reactive antibodies (PRA) &gt;20% (per CDC-based assay)&#xD;
&#xD;
               -  malignancy or previous malignancy, except for adequately treated skin cancers&#xD;
                  (basal cell or squamous cell carcinoma) within the past 5 years&#xD;
&#xD;
               -  sensitivity to iodine and/or shellfish (re: Iothalamate-based GFR testing)&#xD;
&#xD;
               -  x-ray evidence of pulmonary infection&#xD;
&#xD;
               -  active infections&#xD;
&#xD;
               -  active peptic ulcer disease, gall stones, hemangioma, cirrhosis or portal&#xD;
                  hypertension&#xD;
&#xD;
               -  serological evidence of HIV, HBSAg or HCV&#xD;
&#xD;
               -  abnormal liver function tests (elevated AST and ALT &gt; 2x upper limit of normal)&#xD;
&#xD;
               -  anemia (hemoglobin) &lt;9 gm/dl&#xD;
&#xD;
               -  serum triglycerides &gt;200 mg/dl&#xD;
&#xD;
               -  serum cholesterol &gt;240 mg/dl&#xD;
&#xD;
               -  body mass index above 28&#xD;
&#xD;
               -  unstable cardiovascular status (including positive stress echocardiography if&#xD;
                  &gt;age 35); severe coexisting cardiac disease, myocardial infarction within the 6&#xD;
                  months prior to enrollment in the study, left ventricular ejection fraction of&#xD;
                  &lt;30%, or evidence of ongoing ischemia&#xD;
&#xD;
               -  prostate specific antigen (PSA) &gt;4 in males &gt;40 years old or with family history&#xD;
                  of prostate cancer&#xD;
&#xD;
               -  pregnancy or breastfeeding&#xD;
&#xD;
               -  sexually-active females who are not: a) post-menopausal, b) surgically sterile,&#xD;
                  or c) not using an acceptable method of contraception (oral contraceptives,&#xD;
                  Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone&#xD;
                  are not acceptable)&#xD;
&#xD;
               -  alcohol abuse, substance abuse or smoking within the previous 6 months&#xD;
&#xD;
               -  insulin requirement &gt;1.5 u/kg/day&#xD;
&#xD;
               -  negative for Epstein-Barr virus by IgG determination&#xD;
&#xD;
               -  history of factor V deficiency&#xD;
&#xD;
               -  acute or chronic pancreatitis&#xD;
&#xD;
               -  recurrent attenuated vaccine(s) within the previous 2 months&#xD;
&#xD;
               -  use of an investigational agent within the past 4 weeks&#xD;
&#xD;
               -  sexually active, fertile men not using effective birth control, if their partners&#xD;
                  are WOCBP&#xD;
&#xD;
               -  prisoners, or subjects who are involuntarily incarcerated&#xD;
&#xD;
               -  subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
                  physical (eg, infectious disease) illness&#xD;
&#xD;
               -  Previous kidney transplant or previous non-renal transplant&#xD;
&#xD;
               -  kidney transplant from expanded criteria donor (ECD)&#xD;
&#xD;
               -  kidney cold ischemic time projected to be &gt; 20 hours&#xD;
&#xD;
               -  currently receiving immunosuppressive agents for autoimmune disease or other&#xD;
                  conditions or have comorbidities that treatment with such agents are likely&#xD;
                  during the trial&#xD;
&#xD;
               -  any condition or circumstance that makes it unsafe to undergo an islet cell or&#xD;
                  kidney transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

